Double-crane Pharmaceutical To Set Up Subsidiary In Liaoning
This article was originally published in PharmAsia News
Beijing Double-crane Pharmaceutical has announced plans to invest RMB 100 million ($14.6 million) to set up a wholly-owned subsidiary named Liaoning Double-crane in Liaoning province, with plans to establish a medical transfusion product line. Present transfusion packaging firms in China's northeast region are small-scale operations producing glass bottles. Plastic transfusion bags are increasingly replacing glass, showing a huge development potential and opportunity for Double-crane. Meanwhile, the company will loan RMB 62.36 million ($9.10 million) to subsidiary Beijing Wanhui Double-crane Pharmaceutical to set up a U.S. FDA-cGMP-compliant solid pharmaceutical formulation base. The move marks the corporation's first concrete step into the American and European market. (Click here for more - Chinese Language)
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.